Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient

Sareena Ali; Sufyan AbdulMujeeb; Ahmed Khattab; Nahren Asado; Marc Fine

doi:10.14309/crj.0000000000000974

Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient

ACG Case Rep J. 2023 Jan 25;10(1):e00974. doi: 10.14309/crj.0000000000000974. eCollection 2023 Jan.

Authors

Sareena Ali¹, Sufyan AbdulMujeeb¹, Ahmed Khattab², Nahren Asado³, Marc Fine²

Affiliations

¹ Department of Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL.
² Department of Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.
³ Department of Pathology, Advocate Lutheran General Hospital, Park Ridge, IL.

Abstract

Many chemotherapeutic agents have been associated with drug-induced colitis (DIC). With newer agents' expansion of approval as first-line therapy for common cancers, it is important to be cognizant of their association with DIC. We present a case of brentuximab-associated DIC in an elderly woman with CD30+ Hodgkin lymphoma. Brentuximab's association with DIC was suspected by others in the literature, but a history of stem-cell transplant in them would blur the association with graft-vs-host disease. Lack of stem-cell transplant in our patient makes the link between brentuximab and DIC unambiguous.

Keywords: colitis; colon.

Publication types

Case Reports